Amb motiu del tancament d'estiu, la validació de documents es reprendrà a partir del 28 d'agost de 2026. Disculpeu les molèsties.
Con motivo del cierre de verano, la validación de documentos se reanudará a partir del 28 de agosto de 2026. Disculpad las molestias
Due to the summer closure, document validation will resume starting August 28, 2026. We apologize for any inconvenience.

Files

del PinoMD.pdf (608.31 KB)

Document type

Article

Version

Published version

Publication date

2018-01-01

Publication license

cc-by-nc-nd (c) Pino, María Dolores del et al., 2018
Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/123997

Fabry Nephropathy: An Evidence-based Narrative Review

Journal Title

Authors

Director/Tutor

Journal ISSN

Volume Title

Related resource

https://doi.org/10.1159/000488121

Abstract

Fabry disease (FD) is a rare, X-linked disorder caused by mutations in the GLA gene encoding the enzyme alpha-galactosidase A. Complete or partial deficiency in this enzyme leads to intracellular accumulation of globotriaosylceramide (Gb3) and other glycosphingolipids in many cell types throughout the body, including the kidney. Progressive accumulation of Gb3 in podocytes, endothelial cells, epithelial cells, and tubular cells contribute to the renal symptoms of FD, which manifest as proteinuria and reduced glomerular filtration rate leading to renal insufficiency. A correct diagnosis of FD, although challenging, has considerable implications regarding treatment, management, and counseling. The diagnosis may be confirmed by demonstrating the enzyme deficiency in males and by identifying the specific GLA gene mutation in male and female patients. Treatment with enzyme replacement therapy, as part of the therapeutic strategy to prevent complications of the disease, may be beneficial in stabilizing renal function or slowing its decline, particularly in the early stages of the disease. Emergent treatments for FD include the recently approved chaperone molecule migalastat for patients with amenable mutations. The objective of this report is to provide an updated overview on Fabry nephropathy, with a focus on the most relevant aspects of its epidemiology, diagnosis, pathophysiology, and treatment options. (C) 2018 The Author(s) Published by S. Karger AG, Basel.

Subject

Malaltia de Fabry, Nefrologia, Proteïnúria

Subject (English)

Fabry's disease, Nephrology, Proteinuria

Citation

Collections

Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Citation

PINO Y PINO, María Dolores del, et al. Fabry Nephropathy: An Evidence-based Narrative Review. Kidney & Blood Pressure Research. 2018. Vol. 43, num. Issue 2, pags. 406-421. [consulted: 17 of August of 2026]. Available at: https://hdl.handle.net/2445/123997

Export metadata

JSON - METS

Share record